Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 349, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.jneuroim.2020.577400
Keywords
SARS-COV-2; Encephalitis; Neurological; Immunotherapy; Cytokines; Delirium
Categories
Ask authors/readers for more resources
Encephalopathy is emerging as a recurrent complication of COVID-19 yet remains poorly characterized. We report the case of a middle-aged woman with COVID-19-related encephalopathy presenting as expressive aphasia and inattentiveness, subsequently progressing to agitation and marked confusion. Brain MRI and CSF analysis were unremarkable, while EEG showed slowing with frontal sharp waves. Neuropsychiatric symptoms resolved following treatment with tocilizumab. CNS involvement in COVID-19 may present as a subacute encephalopathy characterized by prominent frontal lobe dysfunction, with language disturbances as first neurological manifestation. Future studies should further investigate the role of tocilizumab in treating COVID-19-related encephalopathy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available